

April 24, 2024

**VIA EDGAR**

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549-3720  
Attention: Chris Edwards

**Re: Acrivon Therapeutics, Inc.  
Registration Statement on Form S-3  
File No. 333-278761**

**Acceleration Request  
Requested Date: April 29, 2024  
Requested Time: 9:00 A.M., Eastern Time**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Acrivon Therapeutics, Inc. (the "Company"), hereby requests that the effective date of the Company's Registration Statement on Form S-3, Registration Number 333-278761 (the "Registration Statement") be accelerated so that the Company's Registration Statement will become effective at 9:00 A.M., Eastern Time, on April 29, 2024, or as soon thereafter as practicable or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission.

We would appreciate it if, as soon as the Registration Statement is declared effective, you would so inform Nick DeAngelis of Sidley Austin LLP at (214) 969-3563 or [ndeangelis@sidley.com](mailto:ndeangelis@sidley.com).

Very truly yours,

/s/ Rasmus Holm-Jorgensen

Rasmus Holm-Jorgensen  
Chief Financial Officer  
Acrivon Therapeutics, Inc.

cc: Mary-Alice Miller, General Counsel and Corporate Secretary  
Istvan Hajdu, Sidley Austin LLP  
Nick DeAngelis, Sidley Austin LLP